Drug intelligence / Profile preview

plodicitinib

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Plodicitinib (DWP212217) is a selective Janus kinase 1 (JAK1) inhibitor being developed by Daewoong Pharmaceutical for the treatment of various autoimmune and inflammatory diseases. By selectively targeting JAK1, the drug aims to modulate the signaling pathways of pro-inflammatory cytokines while minimizing the side effects associated with the inhibition of other JAK family members, such as JAK2-mediated hematological toxicities (e.g., anemia or neutropenia). The compound is a small molecule designed for oral administration and is currently undergoing clinical evaluation to assess its safety, tolerability, and efficacy in conditions such as rheumatoid arthritis.

Other names: plodicitinib

Targets

JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)JAK3 (Janus kinase 3)JAK2 (Janus kinase 2)

Beyond the preview

Go deeper on plodicitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on plodicitinib.

Explore the full profile